Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company’s lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women’s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the company’s research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women’s and men’s health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson’s disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

3 days ago

Alignmt LLC

All business owners will exit at some time, whether via #mergersandacquisitions, transitioning out or a succession plan. Want to maximize value when it’s time for your #acquisition? buff.ly/2ZOlojn

#manda #alignmentmap
... See MoreSee Less

View on Facebook

4 days ago

Alignmt LLC

Do you use relative valuation every day to inform you of what's driving value in your industry? buff.ly/34A8Qv1

#mergersandacquisitions #manda #alignmentmap
... See MoreSee Less

View on Facebook

4 days ago

Alignmt LLC

Some companies manage to jump from #startup to #ipo, but most will follow the risk and value evolution by working hard. What's your plan? buff.ly/34zJmh6

#mergersandacquisitions #manda #alignmentmap
... See MoreSee Less

View on Facebook

4 days ago

Alignmt LLC

Know the difference between strategic and financial buyers? It can make all the difference in your #mergersandacquisitions deal. buff.ly/2ZNfLSB

#manda #alignmentmap
... See MoreSee Less

View on Facebook

Check out my latest article: Investor Presentation Tips: 11 Steps to Writing an Effective Investor Deck https://t.co/M44ebxalYm via @LinkedIn

Want to maximize your business valuation? First things first when thinking about selling. https://t.co/5eZf2JKfts

Load More...

Neurocrine Biosciences, Inc.

12780 El Camino Real
San Diego, CA 92130

+1 (858) 617-7600

www.neurocrine.com

September 2019
S M T W T F S
« Aug    
1234567
891011121314
15161718192021
22232425262728
2930  

©2019 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account